牛牛AI助理已提取核心訊息
On February 27, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, announced in collaboration with Clearmind Medicine Inc., the filing of three new international patent applications. These applications, submitted under the Patent Cooperation Treaty (PCT), cover novel compositions of MDMA, ibogaine, and ketamine, each combined with palmitoylethanolamide (PEA), an active ingredient in SciSparc's CannAmide™. The patents aim to develop therapies for central nervous system disorders and rare diseases. Previously, provisional patents for these compounds were filed with the United States Patent and Trademark Office (USPTO). Additionally, Clearmind has filed eight other USPTO applications and seven PCT applications for various combinations, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. SciSparc specializes in cannabinoid-based pharmaceuticals and is currently working on drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus.
On February 27, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, announced in collaboration with Clearmind Medicine Inc., the filing of three new international patent applications. These applications, submitted under the Patent Cooperation Treaty (PCT), cover novel compositions of MDMA, ibogaine, and ketamine, each combined with palmitoylethanolamide (PEA), an active ingredient in SciSparc's CannAmide™. The patents aim to develop therapies for central nervous system disorders and rare diseases. Previously, provisional patents for these compounds were filed with the United States Patent and Trademark Office (USPTO). Additionally, Clearmind has filed eight other USPTO applications and seven PCT applications for various combinations, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. SciSparc specializes in cannabinoid-based pharmaceuticals and is currently working on drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus.
2024年2月27日，處於臨床階段的製藥公司ScisPARC Ltd. 宣佈與Clearmind Medicine Inc. 合作提交了三項新的國際專利申請。這些根據《專利合作條約》（PCT）提交的申請涵蓋了****、伊博加因和****的新成分，每種成分都與棕櫚酰乙醇胺（PEA）（ScisPARC的CannaMide™ 中的一種活性成分）結合在一起。這些專利旨在開發中樞神經系統疾病和罕見疾病的療法。以前，這些化合物的臨時專利是向美國專利商標局（USPTO）申請的。此外，Clearmind還提交了另外八份美國專利商標局申請和七份不同組合的PCT申請，包括酒精使用障礙、可卡因成癮和肥胖相關代謝障礙的治療。ScisPARC專門研究基於大麻素的藥物，目前正在研究針對圖雷特綜合症、阿爾茨海默氏病、疼痛、自閉症障礙和癲癇持續狀態等疾病的藥物開發項目。
2024年2月27日，處於臨床階段的製藥公司ScisPARC Ltd. 宣佈與Clearmind Medicine Inc. 合作提交了三項新的國際專利申請。這些根據《專利合作條約》（PCT）提交的申請涵蓋了****、伊博加因和****的新成分，每種成分都與棕櫚酰乙醇胺（PEA）（ScisPARC的CannaMide™ 中的一種活性成分）結合在一起。這些專利旨在開發中樞神經系統疾病和罕見疾病的療法。以前，這些化合物的臨時專利是向美國專利商標局（USPTO）申請的。此外，Clearmind還提交了另外八份美國專利商標局申請和七份不同組合的PCT申請，包括酒精使用障礙、可卡因成癮和肥胖相關代謝障礙的治療。ScisPARC專門研究基於大麻素的藥物，目前正在研究針對圖雷特綜合症、阿爾茨海默氏病、疼痛、自閉症障礙和癲癇持續狀態等疾病的藥物開發項目。
有用
沒用